This site is intended for healthcare professionals

Phase III SCORED trial of Zynquista shows improvements in patients with type 2 diabetes and chronic kidney disease.- Lexicon Pharma

Read time: 1 mins
Published:3rd Apr 2022

Lexicon Pharmaceuticals announced results of a new analysis of data from the SCORED Phase III clinical trial of Zynquista (sotagliflozin) in patients with type 2 diabetes and chronic kidney disease. The SCORED clinical trial randomized 10,584 patients with type 2 diabetes and chronic kidney disease to sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, or placebo.


Treatment with sotagliflozin resulted in a significant reduction in major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in the entire cohort as compared to placebo. This analysis also evaluated the effect of sotagliflozin on MACE in prespecified subgroups of patients with cardiovascular disease (CVD; n=5,144) and without CVD (n=5,440) at baseline. The analysis showed consistent reductions in MACE in both subgroups with a relative risk reduction in MACE of 21% in patients with and 26% in patients without CVD, in each case compared to placebo. The analysis demonstrates that in addition to reducing heart failure events, sotagliflozin reduced MACE events. The lower rates of MACE, notably including reductions in both heart attack and stroke, were consistent in patients with and without cardiovascular disease at baseline.

The data were presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22). The presentation was entitled, “Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, and Stroke in the SCORED Trial”.

Condition: Diabetes Type 2 and Kidney Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights